HPV testing 3

• OC 10-01 • The BD Onclarity™ HPV assay on surepath collected samples meets the international guidelines for human papillomavirus test requirements for cervical screening. See abstract > D. Ditte møller Ejegod • OC 10-02 • Comparison of BD onclarity HPV assay to Roche Cobas 4800 HPV tests in cervical screening in England See abstract > K. Kay Ellis • OC 10-03 • Head-to-head comparison of the Abbott realtime high risk HPV test and the Roche Cobas 4800 HPV test in population-based cervical cancer screening setting See abstract > A. Anja Ostrbenk • OC 10-04 • Triage of women with Low-grade squamous intraepithelial lesion (LSIL) by detection of Human Papillomavirus transformed clonal populations See abstract > W. Wiebren Tjalma • OC 10-05 • HPV 18 detection variability between APTIMA® HPV 16 18/45 genotype and the cobas® HPV assay See abstract > S. S.S. Beqaj • OC 10-06 • Performance of HPV-E7 oncoprotein detection as a triage method to colposcopy for HPV 16/18 positive women, compared to no triage, or for high-risk HPV (non 16/18) positive women, compared to cytology. Results of the Pipavir study See abstract > K. Kimon Chatzistamatiou • OC 10-07 • The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples > R. Renee Ebisch